Vale Julien Do, Kantor Elie, Papin Grégory, Sonneville Romain, Braham Wael, Para Marylou, Montravers Philippe, Longrois Dan, Provenchère Sophie
Anesthesiology and Surgical Critical Care Department, DMU PARABOL, AP-HP, Bichat Hospital, Paris, France.
Department of Intensive Care Medicine and Infectious Diseases, AP-HP, Bichat Hospital, Paris, France.
Perfusion. 2025 May;40(4):858-868. doi: 10.1177/02676591241261330. Epub 2024 Jun 12.
RationaleFor veno-arterial extracorporeal membrane oxygenation (ECMO), the femoral artery is the preferred cannulation site (femoro-femoral: Vf-Af). This results in retrograde aortic flow, which increases the left ventricular afterload and can lead to severe pulmonary edema and thrombosis of the cardiac chambers. Right axillary artery cannulation (femoral-axillary: Vf-Aa) provides partial anterograde aortic flow, which may prevent some complications. This study aimed to compare the 90-day mortality and complication rates between VF-AA and VF-AF.MethodsConsecutive adult patients with cardiogenic shock who received peripheral VA-ECMO between 2013 and 2019 at our institution were retrospectively included. The exclusion criteria were refractory cardiac arrest, multiple VA-ECMO implantations due to vascular access changes, weaning failure, or ICU readmission. A statistical approach using inverse probability of treatment weighting was used to estimate the effect of the cannulation site on the outcomes. The primary endpoint was the 90-day mortality. The secondary endpoints were vascular access complications, stroke, and other complications related to retrograde blood flow. Outcomes were estimated using logistic regression analysis.ResultsVA-ECMO was performed on 534 patients. Patients with refractory cardiac arrest ( = 77 (14%)) and those supported by multiple VA-ECMO ( = 92, (17%)) were excluded. Out of the 333 patients studied ( = 209 Vf-Aa; = 124 VF-AF), the main indications for VA-ECMO implantation were post-cardiotomy (33%, = 109), dilated cardiomyopathy (20%, = 66), post-cardiac transplantation (15%, = 50), acute myocardial infarction (14%, = 46) and other etiologies (18%, = 62). The median SOFA score was 9 [7-11], and the crude 90-day mortality rate was 53% ( = 175). After IPTW, the 90-day mortality was similar in the Vf-Aa and VF-AF groups (54% vs 58%, IPTW-OR = 0.84 [0.54-1.29]). Axillary artery cannulation was associated with significantly fewer local infections (OR = 0.21, 95% CI:0.09-0.51), limb ischemia (OR = 0.37, 95% CI:0.17-0.84), bowel ischemia (OR = 0.16, 95% CI:0.05-0.51) and pulmonary edema (OR = 0.52, 95% CI:0.29-0.92) episodes, but with a higher rate of stroke (OR = 2.87, 95% CI:1.08-7.62) than femoral artery cannulation.ConclusionCompared to VF-AF, axillary cannulation was associated with similar 90-day mortality rates. The high rate of stroke associated with axillary artery cannulation requires further investigation.
理论依据
对于静脉-动脉体外膜肺氧合(ECMO),股动脉是首选的插管部位(股-股:Vf-Af)。这会导致主动脉逆行血流,增加左心室后负荷,并可能导致严重肺水肿和心腔血栓形成。右腋动脉插管(股-腋:Vf-Aa)可提供部分主动脉顺行血流,这可能预防一些并发症。本研究旨在比较Vf-Aa和Vf-Af之间的90天死亡率和并发症发生率。
方法
回顾性纳入2013年至2019年在本机构接受外周VA-ECMO治疗的心源性休克成年连续患者。排除标准为难治性心脏骤停、因血管通路改变、撤机失败或入住重症监护病房(ICU)再次入院而进行多次VA-ECMO植入。采用治疗权重逆概率的统计方法来估计插管部位对结局的影响。主要终点是90天死亡率。次要终点是血管通路并发症、中风和其他与逆行血流相关的并发症。使用逻辑回归分析估计结局。
结果
对534例患者进行了VA-ECMO治疗。排除难治性心脏骤停患者(n = 77(14%))和接受多次VA-ECMO支持的患者(n = 92,(17%))。在研究的333例患者中(n = 209例Vf-Aa;n = 124例Vf-Af),VA-ECMO植入的主要指征是心脏手术后(33%,n = 109)、扩张型心肌病(20%,n = 66)、心脏移植后(15%,n = 50)、急性心肌梗死(14%,n = 46)和其他病因(18%,n = 62)。序贯器官衰竭评估(SOFA)评分中位数为9[7-11],90天粗死亡率为53%(n = 175)。经过治疗权重逆概率(IPTW)后,Vf-Aa组和Vf-Af组的90天死亡率相似(54%对58%,IPTW比值比=0.84[0.54-1.29])。腋动脉插管与局部感染(比值比=0.21,95%置信区间:0.09-0.51)、肢体缺血(比值比=0.37,95%置信区间:0.17-0.84)、肠缺血(比值比=0.16,95%置信区间:0.05-0.51)和肺水肿(比值比=0.52,95%置信区间:0.29-0.92)发作显著减少相关,但与股动脉插管相比,中风发生率更高(比值比=2.87,95%置信区间:1.08-7.62)。
结论
与Vf-Af相比,腋动脉插管的90天死亡率相似。与腋动脉插管相关的高中风发生率需要进一步研究。